Hai-feng Cheng1,
Yan Feng2 
,
Qun-jun Duan1,
Da-Ming Jiang1,
Kai-Yu Tao1
For correspondence:- Yan Feng Email: fengyan31900@gmail.com Tel:+8657187784704
Received: 12 February 2015 Accepted: 23 May 2015 Published: 29 June 2015
Citation: Cheng H, Feng Y, Duan Q, Jiang D, Tao K. Floating microparticulate oral diltiazem hydrochloride delivery system for improved delivery to heart. Trop J Pharm Res 2015; 14(6):935-940 doi: 10.4314/tjpr.v14i6.1
© 2015 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..
Purpose: To formulate and evaluate floating microparticulate oral diltiazem delivery system for possible delivery to the heart.
Methods: Floating microspheres were prepared using cellulose acetate and Eudragit RS100 polymers by emulsion solvent evaporation technique. The dried floating microspheres were evaluated for micromeritic properties (flow properties, density, particle size determination) scanning as well as by electron microscopy, and in vitro floatability and drug release studies.
Results: The microspheres showed good buoyancy, good flow properties (angle of repose ranging from 24.29 to 29.02 º), particle size (262.09 to 409.60 µm) and good drug loading (74.29 to 92.09 %). The microspheres were porous, hollow and spherical. All the formulations showed good in vitro controlled drug release in the range of 77.62 ± 2.12 to 97.50 ± 1.04 % at the end of 12 h. Drug release was diffusion-controlled and followed zero order kinetics.
Conclusion: Microparticulate floating (gastroretentive) oral drug delivery system of diltiazem prepared using cellulose acetate and Eudragit R5100 may be an effective alternative to conventional oral tablets for cardiac drug delivery.
Fulltext in PDF